Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6990292 | 0.94 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2A6 | |
| SCHEMBL6985110 | 0.74 | MEN1 (0.35) | — | |
| SCHEMBL3150179 | 0.68 | CYP2A6 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2A6 | |
| SCHEMBL6581524 | 0.68 | IMPDH2 (0.41) | SLC6A2SLC6A4SLC6A3CYP2A6 | |
| SCHEMBL25639101 | 0.67 | FYN (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2A6 | |
| SCHEMBL25639105 | 0.67 | FYN (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2A6 | |
| SCHEMBL25639098 | 0.67 | FYN (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2A6 | |
| SCHEMBL3028639 | 0.67 | TRPM5 (0.41) | SLC6A2SLC6A4 | |
| SCHEMBL10292643 | 0.66 | FYN (0.40) | — | |
| SCHEMBL20260136 | 0.66 | CYP2A6 (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146041-B1 | Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline | SERVIER LAB (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-6420413-B2 | 1-(6-((DIMETHYLAMINO)METHYL)-1-METHYL-2,3,5,6-TETRAHYDRO-1H -CYCLOBUTA(F) INDOL-6-YL)CYCLOHEXANOL, FOR EXAMPLE; TREATING PSYCHOLOGICAL DISORDERS SUCH AS DEPRESSION, PANIC ATTACKS, PHOBIAS, DRUG ABUSE, AS WELL AS OBESITY AND BULEMIA | LES LABORATORIES SERVIER (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | LES LABORATOIRES SERVIER (FR) | 2002-02-14 | — | — | US | disclosed |
| EP-1146041-A1 | Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline | ADIR ET COMPAGNIE (FR) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | HSD3B2, HSD3B1, NR1H3 | SLC6A2 760/4885SLC6A4 667/4885SLC6A3 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.